For what it' s worth...
Immunotherapies currently has 4 studies - HSV2 (now waiting for a partner) plus three HPV projects all of which have only just started or about to start.
In other words there aren't going to be any results for a year or so...
WP has also said every dime will be turned over twice before being spent.
Personally, I'll revisit immunotherapies in a year or so.
It's all about Adapt and going CF+ in Q1 FY18 (and nothing else).
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-312
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.53 |
Change
-0.025(0.13%) |
Mkt cap ! $363.6M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.39 | $116.2K | 6.241K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4 | $18.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.70 | 185 | 3 |
View Market Depth
| Last trade - 14.25pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |